Brief: Oxigene granted European patent for drug used in acute myeloid leukemia and other myeloid malignancies
17/11/2014 21:01
Nov 17 (Reuters) - OXiGENE Inc OXGN.O : * Says issuance of European patent for oxi4503 in acute myeloid leukemia and other myeloid malignancies * Source text for Eikon ID:nGNXVCCOUa * Further company coverage OXGN.O ((Bangalore Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas